Zytoprotec is developing drugs for diseases that affect millions of patients, using a novel therapeutic approach–cytoprotection.

Zytoprotec’s most advanced drug candidate, PD-protec^™, is currently in Phase I/II of clinical development. PD-protec^™ is based on a patent-protected cytoprotective compound and is designed to improve survival in renal replacement therapy (peritoneal dialysis).

Other programs focus on the development of cytoprotective therapies for diabetes and other major disease areas. In addition, the Company offers research services to industrial partners, exploring cytoprotective properties of successful drugs and potentially creating new intellectual property.